| __timestamp | Intra-Cellular Therapies, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 241751000 |
| Thursday, January 1, 2015 | 139626 | 322292000 |
| Friday, January 1, 2016 | 93831530 | 344320000 |
| Sunday, January 1, 2017 | 79419009 | 374644000 |
| Monday, January 1, 2018 | 368673 | 1820000 |
| Tuesday, January 1, 2019 | 477121 | 4000000 |
| Wednesday, January 1, 2020 | 1895029 | 12000000 |
| Friday, January 1, 2021 | 8034589 | 11000000 |
| Saturday, January 1, 2022 | 20443000 | 14000000 |
| Sunday, January 1, 2023 | 33745000 | 9133000 |
| Monday, January 1, 2024 | 11215000 |
Unlocking the unknown
In the competitive world of biotechnology, cost efficiency can be a decisive factor for success. This analysis compares the cost of revenue efficiency between Intra-Cellular Therapies, Inc. and Ionis Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Ionis Pharmaceuticals consistently reported higher costs, peaking in 2017 with a staggering 374% more than Intra-Cellular Therapies. However, a notable shift occurred in 2018 when Ionis reduced its costs by 99%, aligning closer to its competitor. Intra-Cellular Therapies, on the other hand, showed a steady increase, culminating in a 59% rise in 2023 compared to 2022. This trend highlights the dynamic strategies employed by these companies to manage their operational expenses. As the biotech industry evolves, understanding these financial maneuvers offers valuable insights into their long-term sustainability and growth potential.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Ionis Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
GSK plc vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Ionis Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Ionis Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.